SCHEMBL673370

SCHEMBL673370

CC(C)(C)n1cc(Br)cn1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.35
ELANE P08246 5/20 0.34
PLAU P00749 4/20 0.34
F2 P00734 1/20 0.34
KLKB1 P03952 1/20 0.34
KMT2A Q03164 2/20 0.33
HDAC8 Q9BY41 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PDK2 Q15119 1/20 0.32
KDM5B Q9UGL1 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23210491 0.79 PDK2 (0.34) ALDH1A1ELANEPLAUF2KLKB1
SCHEMBL21819400 0.79 ALDH1A1 (0.32) ALDH1A1ELANEPLAUF2KLKB1
SCHEMBL21794979 0.79 ELANE (0.34) ALDH1A1ELANEPLAUF2KLKB1
SCHEMBL21819552 0.79 ALDH1A1 (0.35) ALDH1A1ELANEPLAUF2KLKB1
SCHEMBL2766588 0.79 ALDH1A1 (0.35) ALDH1A1ELANEPLAUF2KLKB1
SCHEMBL21995832 0.77 ELANE (0.40) ALDH1A1ELANEPLAUF2KLKB1
SCHEMBL18603248 0.77 F2 (0.37) ALDH1A1ELANEPLAUF2KLKB1
SCHEMBL25341415 0.77 ALDH1A1 (0.31) ALDH1A1ELANEPLAUF2KLKB1
SCHEMBL1582031 0.77 KIT (0.43) ALDH1A1ELANEPLAUF2KLKB1
SCHEMBL3766982 0.77 LMNA (0.43) ALDH1A1ELANEPLAUF2KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735431-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2026-05-06 EP disclosed
EP-4720036-A1 CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF 16380026 Canada Inc. (CA) 2026-04-08 EP disclosed
US-12239630-B2 Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-03-04 US disclosed
CN-115068468-B Carboxylic aromatic amides as bradykinin B1 receptor antagonists 拜耳制药股份公司 2025-02-25 CN disclosed
US-20250051309-A1 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. 2025-02-13 US disclosed
WO-2025006568-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2025-01-02 WO disclosed
WO-2024243692-A1 CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF QUEEN'S UNIVERSITY AT KINGSTON (CA) 2024-12-05 WO disclosed
CN-108368040-B Diaryl monocyclic beta-lactam compounds and methods for their use in the treatment of bacterial infections 默沙东有限责任公司 2024-08-23 CN disclosed
CN-115137726-B Carboxylic aromatic amides as bradykinin B1 receptor antagonists 拜耳制药股份公司 2024-08-13 CN disclosed
US-12023319-B2 Carboxylic acid aromatic amides BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2024-07-02 US disclosed
US-7566735-B2 Compounds which potentiate AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2009-07-28 US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20090137566-A1 Substituted Piperdines as Renin Inhibitors EHARA TAKERU 2009-05-28 US disclosed
US-20090118280-A1 Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine HARRISON STEPHEN 2009-05-07 US disclosed
US-20090118280-A1 Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine HARRISON STEPHEN 2009-05-07 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO disclosed
US-20080045532-A1 Compounds which potentiate AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2008-02-21 US disclosed
US-20080045532-A1 Compounds which potentiate AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12023319-B2 Carboxylic acid aromatic amides DDC, PAH, NAT1 ALDH1A1 135/4885ELANE 1203/4885PLAU 4644/4885
US-20250051309-A1 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME DUSP2, MKNK2, DUSP22 ALDH1A1 4336/4885ELANE 2335/4885PLAU 3405/4885
US-12239630-B2 Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor BDKRB1, BDKRB2, HCAR1 ALDH1A1 861/4885ELANE 1138/4885PLAU 2105/4885
US-20090118280-A1 Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine GRIN1, GRM2, GRM1 ALDH1A1 1395/4885ELANE 3813/4885PLAU 3503/4885
US-20090137566-A1 Substituted Piperdines as Renin Inhibitors REN, ACE, AGTR1 ALDH1A1 127/4885ELANE 1128/4885PLAU 564/4885
US-20080045532-A1 Compounds which potentiate AMPA receptor and uses thereof in medicine GRIN1, GRM2, GRM1 ALDH1A1 1395/4885ELANE 3813/4885PLAU 3503/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 ALDH1A1 1389/4885ELANE 4282/4885PLAU 3283/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 ALDH1A1 1389/4885ELANE 4282/4885PLAU 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.